Blood transfusion as a risk factor for non-Hodgkin lymphoma. by Brandt, L. et al.
British Journal of Cancer (1996) 73, 1148-1151
©3 1996 Stockton Press All rights reserved 0007-0920/96 $12.00
Blood transfusion as a risk factor for non-Hodgkin lymphoma
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Summary In a case-control study of 280 out of 426 consecutive patients with a recent diagnosis of non-
Hodgkin lymphoma (NHL) and 1827 control subjects, 53 (19%) and 230 (13%) respectively had received blood
transfusions 1 year or more before the interview. Using an age- and sex-stratified analysis the odds ratio (OR)
for transfusion was 1.74 (95% CI 1.24-2.44). ORs were also determined for transfusions received in the
intervals 1 -5, 6-15, 16-25 and >26 years before diagnosis. In the interval 6-15 years, the OR for
transfusion was 2.83 (95% CI 1.60-4.99) whereas ORs for transfusions received in other intervals were lower
and not significantly elevated. Histological diagnoses (Kiel classification) and results of staging procedures were
known for 185 patients. For low-grade NHL of nodal B-cell chronic lymphocytic leukaemia (B-CLL) or
immunocytoma type, the OR for transfusions was 4.15 (95% CI 1.92-9.01). For low-grade nodal lymphomas
of follicle centre cell type and high-grade nodal lymphomas, no relation to transfusions could be demonstrated.
For high-grade extranodal lymphoma as sole manifestation, OR for transfusions was 3.27 (95% CI 1.30-8.24).
It is concluded that blood transfusion may be a risk factor for NHLs especially those of B-CLL or
immunocytoma type and for high-grade extranodal lymphoma.
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The incidence of non-Hodgkin lymphoma (NHL) is
increasing quite rapidly in many populations, including
Scandinavia (Coleman et al., 1993, Carli et al., 1994,
Cartwright et al., 1994, National Board of Health and
Welfare, 1995). The causes of this increase are unknown, and
in an attempt to identify risk factors for NHL a case-control
study has been initiated in the Southern Health Care Region
of Sweden.
According to cohort studies of cancer morbidity in blood
recipients, transfusions may be a risk factor for NHL. In a
Swedish study (Blomberg et al., 1993) an excess of NHL was
observed in previously transfused subjects, the standardised
morbidity ratio being 4.09 (95% CI 1.65-8.43). Cerhan et al.
(1993) obtained information about past transfusions from
women aged 55-69 years who were resident in Iowa and
followed up for 5 years. For women who had ever received a
blood transfusion the relative risk of NHL was 2.20 (95% CI
1.35-3.58). Memon and Doll (1994) identified nearly 13 000
infants who received blood transfusions shortly after birth in
England, Wales and Scotland and recorded the incidence of
subsequent malignant tumours. The incidence of NHL at
15-49 years of age was about twice that expected, but the
excess was not statistically significant.
Our ongoing case-control study offered an opportunity to
further evaluate the relation between previous blood
transfusions and the development of NHL. We report here
on the association between transfusions and NHL. The
relation between the time lapse since transfusion and the risk
of lymphoma has also been studied.
Subjects and methods
Patients
All patients in the Southern Health Care Region of Sweden
with a recent diagnosis of malignancy are reported to the
Southern Swedish Regional Tumour Registry. Starting in
1991 adult patients with NHL are asked to complete a
questionnaire containing items regarding previous diseases,
family history of disease, medication, various life-style
factors, occupations. The questionnaire contains an item
asking 'Have you ever had a blood transfusion?' If the
answer is yes, the patient is asked to state the year of
transfusion. The reason for the blood transfusion is not
asked. At the time of compiling this report the questionnaire
has been mailed to 426 NHL patients and 298 (70%) have
responded. Of these, 184 are men and 114 women aged 17-
92 years (median 63). Of the responding patients, 18 (6%)
were excluded from the analyses because of incomplete
answers concerning transfusions, leaving 280 for analysis.
The case records for the responding patients have been
searched for and at present histological type of lymphoma
and the results of the staging procedures are known for 185
patients. The Kiel classification of lymphomas is used
(Stansfeld et al., 1988). In our region a uniform programme
for the diagnosis, staging and treatment of NHL is followed.
The few relevant pathologists already participate in the
programme and a histological review of the lymphomas was
not considered necessary. Four categories of NHL were
studied:
1 low-grade nodal with or without advanced disease;
2 low-grade extranodal;
3 high-grade nodal with or without advanced disease;
4 high-grade extranodal.
In a parallel case-control study the same questionnaire as
for the lymphoma patients was mailed to 240 patients with a
recent diagnosis of sarcoma, of whom 187 have responded.
Their answers concerning transfusions were used to evaluate
possible recall bias among patients with malignant tumours.
Controls
Control subjects were selected from the General Population
Registry and matched with the lymphoma and sarcoma
patients for sex, age and residence. The same questionnaire as
the one used for the lymphoma and sarcoma patients was
mailed to all controls. About 3500 questionnaires have been
mailed and 705 lymphoma controls and 1226 sarcoma
controls have answered, of whom 1009 are men and 922
women, their median age being 66 years. Of the responding
controls, 104 (5.4%) were excluded from the analyses because
of incomplete answers about transfusion, leaving 1827
controls for analysis.
Statistical methods
Odds ratios (ORs) for having received a blood transfusion at
any time and in various intervals before the interview were
determined by means of multivariate logistic regression
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November 1995(Breslow and Day, 1980). Transfusions received less than 1
year before the interview were not considered because recent
transfusions might be due to anaemia caused by the
malignant disease. For earlier transfusions the time was
categorised into four groups 1-5, 6-15, 16-25 and more
than 25 years. Transfusions in these periods were represented
by indicator variables and it was then noticed that a few
persons were transfused in two or more intervals. All analyses
were stratified by sex and 10 year age groups using indicator
stratifying variables. Residence was not used because
indications for medical procedures, including transfusions,
are relatively uniform in the Health Care Region.
Controls in the lymphoma and sarcoma studies with the
same values of matching variables are exchangeable, because
they have been randomly selected from the same population
and have answered the same questionnaire. To improve the
statistical power, especially in the lymphoma subgroups, all
controls were pooled into one large group in all analyses.
The computer program Stata (StataCorp., 1995) was used
for all statistical analyses.
Results
Overall risk of transfusions
A history of transfusion was admitted or denied by 280 NHL
patients and 1827 controls. The numbers of transfused
patients and controls were 53 (19%) and 230 (13%)
respectively. Using an age- and sex-stratified analysis the
OR was 1.74, 95% CI 1.24-2.44 (Table I). For transfusions
received 6-15 years before diagnosis the OR was 2.83, 95%
CI 1.60-4.99 (Table II). The ratios for earlier or later
transfusions were elevated but not statistically significant
(Table II).
Low-grade nodal lymphoma
Among the patients for whom histological diagnosis and
results of clinical staging were available, 82 had low-grade
nodal lymphoma with or without disseminated disease and 18
(22%) of these had been transfused; OR for a transfusion
history was 2.02, 95% CI 1.16-3.51 (Table I).
In a small subgroup of 31 patients with lymphoma of B-
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CLL or lymphoplasmacytoid (immunocytoma) type, 11
(35%) had received transfusions; OR=4.15, 95% CI 1.92-
9.01 (Table I). In the interval 6-15 years before diagnosis the
OR was 8.12, 95% CI 2.95-22.3, whereas ORs for earlier or
later transfusions were slightly but not significantly elevated
(Table II).
A total of 44 patients had low-grade lymphoma of follicle
centre cell type (centrocytic, centroblastic/centrocytic) and
five (11%) had a history of transfusion with a non-significant
OR=0.91, 95% CI 0.35-2.36 (Table I). Seven other patients
had unclassified low-grade lymphomas, of whom two had
received transfusions.
Low-grade extranodal lymphoma
Only eight patients presented with low-grade extranodal
lymphoma as the sole initial manifestation and one of these
(13%) had received a transfusion (Table I).
Table I Number of transfused patients and controls. Odds ratios
(OR) for all NHL cases and subgroups and for sarcoma cases as an
additional comparison group
Transfused
Diagnosis n n (%) OR 95% CI
All NHL 280 53 (19%) 1.74 1.24-2.44
Low-grade nodal 82 18 (22%) 2.02 1.16-3.51
B-CLL or immunocytoma 31 11 (35%) 4.15 1.92-9.01
Follicle centre cell 44 5 (11%) 0.91 0.35-2.36
Low-grade extranodal 8 1 (13%) 1.07 0.13-9.09
High-grade nodal 73 10 (14%) 1.25 0.63-2.51
High-grade extranodal 22 7 (32%) 3.27 1.30-8.24
Sarcoma 187 26 (14%) 1.09 0.70-1.70
Controls 1827 230 (13%)
Table II Odds ratios (95% CI) for transfusions received in various intervals before diagnosis. Number of transfused subjects in parentheses
Time before diagnosis (years)
Diagnosis 1-5 6-15 16-25 >26
All NHL 1.67 2.83 1.55 1.45
(n=280) (0.87-3.21) (1.60-4.99) (0.80-2.99) (0.80-2.60)
(13) (19) (12) (15)
Low-grade nodal 1.50 4.90 1.22 1.55
(n=82) (0.50-4.50) (2.25-10.7) (0.36-4.13) (0.54-4.47)
(4) (9) (3) (4)
B-CLL or immunocytoma 2.89 8.12 2.04 1.34
(n =31) (0.87-9.66) (2.95-22.3) (0.44-9.53) (0.17-10.6)
(4) (6) (2) (1)
Follicle centre cell 0 2.93 0.72 0.56
(n=44) (no transfused) (0.85-10.1) (0.09-5.5) (0.07-4.18)
(0) (3) (1) (1)
High-grade nodal 1.61 1.11 2.32 0.37
(n=73) (0.48-5.45) (0.26-4.79) (0.80-6.74) (0.05-2.71)
(3) (2) (4) (1)
Low-grade extranodal
(n =8)a
High-grade extranodal 1.45 8.58 2.83 2.33
(n =22) (0.17- 12.32) (2.62-28.0) (0.60- 13.3) (0.51 -10.6)
(1) (4) (2) (2)
Sarcoma 1.53 1.48 0.53 1.44
(n= 187) (0.67-3.50) (0.65-3.38) (0.16-1.75) (0.76-2.72)
(7) (7) (3) (12)
aToo few cases for analysis.Transfusions and risk of NHL
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High-grade nodal lymphoma
Of the 73 patients in this group ten (14%) had been
transfused; OR= 1.25, 95% CI 0.63-2.51 (Table I). Five of
the transfused patients had centroblastic lymphoma, three
unclassified high grade B-cell lymphoma, one immunoblastic
lymphoma and one anaplastic large cell T-cell lymphoma.
High-grade extranodal lymphoma
A total of 22 patients had high-grade extranodal lymphoma
as sole manifestation and seven (32%) had received
transfusions; OR=3.27, 95% CI 1.30-8.24 (Table I). Four
of these were transfused 6- 15 years before diagnosis,
OR=8.58, 95% CI 2.62-28.0 (Table II). Clinical and
histological data for the seven transfused patients are shown
in Table III.
Sarcoma patients
Among 187 patients with sarcoma, 26 (14%) had a
transfusion history; OR= 1.09, 95% CI 0.70- 1.70. The OR
was not significantly elevated in any of the intervals analysed
(Table II).
Reasons for transfusion
Although the reason for transfusion was not requested in the
questionnaire, most patients added this information sponta-
neously. In the subgroup with nodal lymphoma of B-CLL or
immunocytoma type, 8 of 11 transfused patients mentioned
the reason for transfusion as did all seven transfused patients
with high-grade extranodal lymphoma. Thus the cause of
transfusion is known for 15 (83%) in the transfusion-related
subgroups. Five were transfused in connection with
urological surgery, three with orthopedic surgery, two with
gynecologic surgery, one with coronary by-pass operation
and three were transfused because of bleeding gastric ulcers.
One patient with caecal lymphoma was transfused 1 year
before diagnosis because of anaemia.
Discussion
The results of this case-control study indicate an increased
risk of NHL for recipients of blood transfusions and are in
line with conclusions from recent cohort studies (Blomberg et
al., 1993; Cerhan et al., 1993). For a subset of the patients,
the histological type and results of staging procedures are
known. Although the numbers of transfused patients were
small in some clinical subgroups of NHL, the results suggest
that a transfusion history may be particularly related to
nodal B-CLL or immunocytoma and to extranodal high-
grade lymphoma. The highest ORs were recorded for
transfusions received 6-15 years before diagnosis. Because
of the small number of patients studied in various intervals,
the confidence intervals for the ORs are wide, so these data
must be interpreted with caution.
It was considered possible that the patients with a
malignant disease might recall transfusions to a larger
extent than control subjects. In the sarcoma patients the
OR for transfusions was, however, about 1.0. It is therefore
unlikely that recall bias is of great importance for the
elevated ORs.
One patient with extranodal high-grade lymphoma in the
caecal region was transfused because of anaemia 1 year
before diganosis. We have therefore considered the possibility
that lymphoproliferative disease might have prompted
transfusion in other cases. Transfusions would then be
particularly common in a period near diagnosis. In the
interval 1-5 years before diagnosis the OR for transfusions
was, however, lower than the OR for transfusions received
6-15 years before diagnosis. In the lymphoma groups
significantly associated with a transfusion history, the
reasons for transfusion were not unusual or related to any
known condition with an increased risk of lymphoma. A
similar pattern of reasons for transfusion was recorded in a
previous study of blood recipients who showed an increase in
NHL (Blomberg et al., 1993). It is therefore unlikely that the
elevated ORs for transfusion were due to the malignant
lymphoma itself or to any predisposing disease.
Immunodeficiency, whether genetic, viral or iatrogenic, is a
well-known risk factor for NHL. Homologous blood
transfusions have some immunosuppressive effect (Fisher et
al., 1980, George and Morello, 1986, Heiss et al., 1993),
although the mechanisms have not yet been elucidated
(Bordin et al., 1994). Lymphomas in transplanted patients
under immunosuppressive treatment are generally of high-
grade morphology and are often extranodal (Starzl et al.,
1984). This is also characteristic of AIDS-associated
lymphomas in which immunosuppression is considered to
be an important determinant of the increased risk (Beral et
al., 1991). The present results also raise the possibility that
immunosuppression caused by transfusions may also increase
the risk of high-grade extranodal lymphomas. However, low-
grade nodal lymphomas of B-CLL or immunocytoma type
were also strongly related to a transfusion history. In post-
transplant patients the incidence of NHL is related to the
aggressiveness of the immunosuppressive regimen (Opelz and
Henderson, 1993). It is conceivable that the immunosuppres-
sive effect of blood transfusions is transient and relatively
weak compared with the post-transplantation situation.
Although immune impairment may be a common determi-
nant for increased risk of NHL in transplanted and
transfused patients, the differences in duration and intensity
of the immunosuppressive state may cause the partly
dissimilar patterns of lymphoma presentation.
In kidney and heart transplant recipients undergoing
immunosuppressive treatment the risk of NHL is 20-120
times higher than normal and is most pronounced during the
first year after transplantation (Opelz and Henderson, 1993).
The far lower risk and the generally longer latency period for
transfused patients may also be due to a relatively weak and
transient immunosuppression in blood recipients.
Transmission in the transfused blood of some blood-borne
oncogenic virus might also account for the association
between transfusions and subsequent NHL. HIV infection
would seem unlikely in the present material. In the past 3
years HIV tests have been included in the laboratory
investigations of patients with a recent diagnosis of NHL at
Table III Clinical and histological data for seven transfused patients with high-grade extranodal lymphomas
Timefrom transfusion
Sex Age at diagnosis (years) Lymphoma location Histology
F 75 1 Caecal region Centroblastic
F 60 10 Skin T-cell, high-grade
M 68 13 Testis Centroblastic
M 63 14 Lung T-cell, anaplastic Ki-l+
M 63 15 Stomach and caecal region Centroblastic
M 66 16 Ascending colon Centroblastic
M 60 20 Stomach CentroblasticTransfusios and risk of Ni
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our department and all have been negative. Some viruses
other than HIV that are spread by infected blood may
possibly cause NHL.
The factors responsible for the increasing incidence of
NHL have not been established. In the search for aetiological
factors it might be rewarding to study clinical subgroups
rather than the whole heterogeneous group of NHL. Such an
approach is supported by our results. A large effect of blood
transfusions was observed only for NHL of B-CLL or
immunocytoma type and high-grade extranodal lymphomas.
For other, relatively large subgroups of NHL. i.e. high-grade
nodal and low-grade follicle centre cell lymphomas. no
relation to previous transfusions was detected.
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